Trial Profile
A phase II study of tandutinib (MLN518) in androgen-independent prostate cancer with bone metastases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tandutinib (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2008 Status changed from recruiting to in progress according to NCT.
- 21 Nov 2006 Status change